Pila Pharma's drug hope receives special FDA status

With the orphan drug designation, the Danish-Swedish biotech firm can look forward to additional incentives before and after a potential approval.

Dorte X. Gram, CEO of Pila Pharma | Photo: Pila Pharma / PR

The US Food and Drug Administration (FDA) has granted its orphan drug designation to Danish-Swedish biotech firm Pila Pharma, the company reports in a press release.

The special designation is given to new treatments for rare diseases and comes with incentives such as tax benefits for clinical trials and prolonged market exclusivity following market authorization.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs